Drugs / PF-08046049
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05571839 | Jan 2023 → Jun 2026 | colorectal neoplasm, cutaneous melanoma, mesothelioma, non-small cell lung carcinoma +1 | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046049 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05571839 ↗ |
| Known as | SGN-BB228 | “A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors” NCT05571839 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenous)” NCT05571839 ↗ |